Paclitaxel is a broad‐spectrum anticancer compound, which was derived mainly from a
medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Resistance to chemotherapy and molecularly targeted therapies is a major problem facing
current cancer research. The mechanisms of resistance to'classical'cytotoxic …

Drug target identification is a crucial step in development, yet is also among the most
complex. To address this, we develop BANDIT, a Bayesian machine-learning approach that …

Natural compounds that target microtubules and disrupt the normal function of the mitotic
spindle have proven to be one of the best classes of cancer chemotherapeutic drugs …

Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an
important therapeutic target in tumour cells. Agents that bind to microtubules have been part …

Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum
based therapy, the standard care for primary ovarian cancer management. A deeper …

Evaluation of the electrostatic properties of biomolecules has become a standard practice in
molecular biophysics. Foremost among the models used to elucidate the electrostatic …

Acclaimed by the worldwide medical community as" a staple reference text in the medical
oncologist's library"(JAMA), DeVita, Hellman, and Rosenberg's Cancer: Principles and …